The selected anti-inflammatory agent, DFMO (2-difluoromethylornithine), reportedly alters immune populations within the tumor microenvironment and inhibits tumor growth by increasing CD8+ infiltration [21,22]. This evidence concerns the gene CD8A and neoplasm.